Skip to main content
Elsevier
View Cart
My account

Biochimica et Biophysica Acta: Molecular Basis of Disease

  • Annual issues: 1 volume, 8 issues

  • ISSN: 0925-4439

BBA Molecular Basis of Disease addresses the biochemistry and molecular genetics of disease processes and models of human disease.Manuscripts should emphas… Read more

Subscription options

Subscription options

SHIPPING UPDATE

Journal orders are currently subject to delays

While we upgrade our fulfilment system. We endeavour to ship Journal orders as soon as possible.

Institutional subscription on ScienceDirect

Request a sales quote

BBA Molecular Basis of Disease addresses the biochemistry and molecular genetics of disease processes and models of human disease.

Manuscripts should emphasize the underlying molecular mechanisms of human disease pathways and provide significant advances to the understanding and/or treatment of these disorders.

Studies in model organisms or systems are strongly recommended in order to validate mechanistic insights.

Topics of interest include, but are not limited to

  • Aging

  • Cancer

  • Cardiovascular diseases

  • Cell death–related diseases

  • Genetic diseases

  • Genetic and epigenetic regulation in diseases

  • Immunological diseases

  • Inflammatory diseases

  • Metabolic diseases

  • Mitochondrial diseases

  • Muscular diseases

  • Neurological diseases

The non-preferred topics for BBADIS include

  • Non-coding RNAs
    Research on non-coding RNAs (microRNAs, lncRNAs, circRNAs, etc.) will be considered only if it provides significantly novel insights into disease mechanisms.

  • Single Cell Line Studies
    Studies involving single cell lines will be considered only if they present significantly novel findings.

  • Computational (in Silico) Studies
    Purely computational works (e.g., Mendelian randomization, molecular docking, molecular dynamics) will generally be declined unless they provide novel insights into disease mechanisms.

  • Disease Biomarkers
    Research on disease biomarkers will be considered only if it relates to the explanation of disease mechanisms.

  • Descriptive or Correlative Studies
    Descriptive or correlative studies (e.g., up/down regulation of gene products, -omics studies without follow-up experiments) will be declined unless they provide mechanistic insights.

  • Natural Products and Traditional Medicine
    Work on natural products, extracts, and traditional medicine will be considered only if single biochemical components are characterized and tested.

  • Clinical Studies and Case Reports
    Clinical studies or case reports without mechanistic insights are outside the scope of the journal.

  • Hypothesis Articles
    Submissions based solely on hypotheses will not be considered.

  • Comparative Genomics Studies
    Comparative genomics studies (e.g., GWAS) will only be considered if they provide specific insights into the structural and/or functional properties of individual genes.

  • Incremental Work
    Research that offers incremental advancements without significant novelty or impact will generally be declined.